Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
55
NAUT Quote, Financials, Valuation and Earnings
Last price:
$3.31
Seasonality move
:
-13.38%
Day range:
$3.12 - $3.43
52-week range:
$0.62 - $4.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.63x
Volume:
218K
Avg. volume:
335.9K
1-year change:
270.47%
Market cap:
$412.7M
Revenue:
--
EPS (TTM):
-$0.47
Analysts' Opinion
-
Consensus RatingNautilus Biotechnology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.00, Nautilus Biotechnology, Inc. has an estimated upside of 21.03% from its current price of $3.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $3.31.
Fair Value
-
According to the consensus of 2 analysts, Nautilus Biotechnology, Inc. has 21.03% upside to fair value with a price target of $4.00 per share.
NAUT vs. S&P 500
-
Over the past 5 trading days, Nautilus Biotechnology, Inc. has underperformed the S&P 500 by -15.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nautilus Biotechnology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nautilus Biotechnology, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Nautilus Biotechnology, Inc. reported revenues of --.
Earnings Growth
-
Nautilus Biotechnology, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Nautilus Biotechnology, Inc. reported earnings per share of -$0.11.
Enterprise value:
344.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$6.5M
Return On Assets:
-27.43%
Net Income Margin (TTM):
--
Return On Equity:
-32.41%
Return On Invested Capital:
-27.95%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$5.7M | -$11.2M | -$6.5M | -$6.4M | -$1.6M | |
| Operating Income | -$76.2M | -$81.5M | -$66.8M | -$20M | -$15.4M | |
| EBITDA | -$70.5M | -$70.3M | -$60.4M | -$13.6M | -$13.8M | |
| Diluted EPS | -$0.51 | -$0.56 | -$0.47 | -$0.14 | -$0.11 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $349.2M | $187.2M | $176.8M | $132.8M | $106M | |
| Total Assets | $398.5M | $350.1M | $305.6M | $242.7M | $191.1M | |
| Current Liabilities | $5.8M | $6.8M | $9.1M | $7.6M | $8M | |
| Total Liabilities | $34.9M | $35.1M | $40.2M | $34M | $34.1M | |
| Total Equity | $363.6M | $314.9M | $265.4M | $208.7M | $157M | |
| Total Debt | $29.1M | $28.3M | $31.1M | $26.4M | $26.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$51.7M | -$59.1M | -$50.7M | -$14.3M | -$12.4M | |
| Cash From Investing | -$43.7M | $66.3M | $35.2M | $37.1M | $787K | |
| Cash From Financing | $368K | $1.1M | $214K | $440K | $101K | |
| Free Cash Flow | -$54.2M | -$61.3M | -$52M | -$14.6M | -$12.6M | |
NAUT
Sector
Market Cap
$412.7M
$23.9M
Price % of 52-Week High
76.68%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
0.04%
-1.88%
1-Year Price Total Return
270.47%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.64
200-day SMA
Buy
Level
$1.57
Bollinger Bands (100)
Buy
Level
1.77 - 2.81
Chaikin Money Flow
Buy
Level
2M
20-day SMA
Buy
Level
$3.04
Relative Strength Index (RSI14)
Buy
Level
55.44
ADX Line
Buy
Level
38.89
Williams %R
Neutral
Level
-51.1475
50-day SMA
Buy
Level
$2.61
MACD (12, 26)
Buy
Level
0.93
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
712.9K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.3634)
Buy
CA Score
(Annual)
Level (-0.2805)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (2.2259)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal M. Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
Stock Forecast FAQ
In the current month, NAUT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NAUT average analyst price target in the past 3 months is $4.00.
-
Where Will Nautilus Biotechnology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nautilus Biotechnology, Inc. share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Nautilus Biotechnology, Inc.?
Analysts are divided on their view about Nautilus Biotechnology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nautilus Biotechnology, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Nautilus Biotechnology, Inc.'s Price Target?
The price target for Nautilus Biotechnology, Inc. over the next 1-year time period is forecast to be $4.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NAUT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nautilus Biotechnology, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NAUT?
You can purchase shares of Nautilus Biotechnology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nautilus Biotechnology, Inc. shares.
-
What Is The Nautilus Biotechnology, Inc. Share Price Today?
Nautilus Biotechnology, Inc. was last trading at $3.31 per share. This represents the most recent stock quote for Nautilus Biotechnology, Inc.. Yesterday, Nautilus Biotechnology, Inc. closed at $3.31 per share.
-
How To Buy Nautilus Biotechnology, Inc. Stock Online?
In order to purchase Nautilus Biotechnology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NAUT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NAUT
Sector
P/E ratio
--
21.37x
PEG ratio
--
-0.01x
P/B ratio
2.63x
1.72x
Price / LTM sales
--
1.45x
Growth Metrics
NAUT
Sector
Revenue growth
--
3.44%
Earnings growth
22.09%
15.03%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.15
-$0.22
Profitability
NAUT
Sector
Profitability FY 2025
-$6.5M
$2.4M
Return on invested capital
-27.95%
-33.32%
Return on assets
-27.43%
-29.45%
Return on equity
-32.41%
-40.29%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
Apr
28
Estimated Next Earnings Date
May
28
Balance Sheet
NAUT
Sector
Total cash
$103.4M
$25.7M
Short term investments
$102.2M
$22.7M
Total assets
$191.1M
$70.6M
Long term debt
$26.2M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
